ClinVar Miner

Submissions for variant NM_000287.4(PEX6):c.488G>C (p.Arg163Pro)

gnomAD frequency: 0.00024  dbSNP: rs778791031
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 7
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Counsyl RCV000664899 SCV000788929 uncertain significance Peroxisome biogenesis disorder 4A (Zellweger); Peroxisome biogenesis disorder 4B 2017-01-04 criteria provided, single submitter clinical testing
Eurofins Ntd Llc (ga) RCV000731346 SCV000859152 uncertain significance not provided 2018-01-23 criteria provided, single submitter clinical testing
Invitae RCV001247917 SCV001421370 uncertain significance Peroxisome biogenesis disorder 2022-10-15 criteria provided, single submitter clinical testing This sequence change replaces arginine, which is basic and polar, with proline, which is neutral and non-polar, at codon 163 of the PEX6 protein (p.Arg163Pro). This variant is present in population databases (rs778791031, gnomAD 0.04%). This variant has not been reported in the literature in individuals affected with PEX6-related conditions. ClinVar contains an entry for this variant (Variation ID: 550215). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Fulgent Genetics, Fulgent Genetics RCV002485520 SCV002792537 uncertain significance Peroxisome biogenesis disorder 4A (Zellweger); Peroxisome biogenesis disorder 4B; Heimler syndrome 2 2022-04-14 criteria provided, single submitter clinical testing
Ambry Genetics RCV002530640 SCV003721089 likely benign Inborn genetic diseases 2021-10-16 criteria provided, single submitter clinical testing This alteration is classified as likely benign based on a combination of the following: population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity.
Revvity Omics, Revvity RCV000731346 SCV003814872 uncertain significance not provided 2019-08-22 criteria provided, single submitter clinical testing
Natera, Inc. RCV001835068 SCV002077343 uncertain significance Zellweger spectrum disorders 2020-01-21 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.